Home / Stocks / PFE

Pfizer (PFE, Pharmaceuticals) Stock Valuation & Fair Value Fairly valued

Pfizer (PFE, Pharmaceuticals) trades at a blended P/E of 9.1, about 19% below its historical normal valuation, with a forward growth estimate of -8.9% and a PEG of —. Analysts' one-year estimates have been hit 55% of the time.

DATA AS OF 2026-08-21
Blended P/E
9.1
Normal P/E
11.2
PEG
—
Fwd growth
-8.9%
Div yield
6.2%
RSI (14)
71.8
Overbought

The Street vs SeerForecast

Wall Street's mean price target for PFE is $28.61 across 26 analysts, 1.9% above the current price. The average analyst rating is Buy. Our SeerForecast read of the same stock, formed without analyst targets: fairly valued. When the two disagree, start your digging there.

Valuation flags

Verdict history

tickerseer's rating has been fairly valued since 2026-06-03.

Price and rating by weekClose moved +7.6 percent from 2026-06-03 to 2026-08-17, with 0 rating changes over 21 recorded weeks.2026-06-03: Fairly valued, close 24.90 (recalculated)2026-06-10: Fairly valued, close 25.16 (recalculated)2026-06-14: Fairly valued, close 25.76 (recalculated)2026-06-16: Fairly valued, close 25.59 (recalculated)2026-06-21: Fairly valued, close 24.78 (recalculated)2026-07-02: Fairly valued, close 23.90 (recalculated)2026-07-06: Fairly valued, close 23.31 (recalculated)2026-07-09: Fairly valued, close 23.83 (recalculated)2026-07-12: Fairly valued, close 23.75 (recalculated)2026-07-13: Fairly valued, close 24.06 (recalculated)2026-07-14: Fairly valued, close 23.83 (recalculated)2026-07-20: Fairly valued, close 24.32 (recalculated)2026-07-22: Fairly valued, close 24.39 (recalculated)2026-07-25: Fairly valued, close 24.54 (recalculated)2026-07-27: Fairly valued, close 24.67 (recalculated)2026-07-31: Fairly valued, close 25.01 (recalculated)2026-08-03: Fairly valued, close 25.012026-08-07: Fairly valued, close 26.76 (recalculated)2026-08-10: Fairly valued, close 26.762026-08-14: Fairly valued, close 26.79 (recalculated)2026-08-17: Fairly valued, close 26.7925272026-06-032026-08-17
Attractively valuedFairly valuedAbove fair valueLarger dot: a stronger reading

Not every point was recorded live. Points marked recalculated apply today's valuation rules to the metrics tickerseer archived that week.

2026-06-03P/E 8.4-25%Fairly valued
2026-06-10P/E 8.4-25%Fairly valued
2026-06-14P/E 8.4-25%Fairly valued
2026-06-16P/E 8.4-25%Fairly valued
2026-06-21P/E 8.4-25%Fairly valued
2026-07-02P/E 7.7-31%Fairly valued
2026-07-06P/E 7.9-30%Fairly valued
2026-07-09P/E 7.9-30%Fairly valued
2026-07-12P/E 7.9-30%Fairly valued
2026-07-13P/E 7.9-30%Fairly valued
2026-07-14P/E 7.9-30%Fairly valued
2026-07-20P/E 8.2-27%Fairly valued
2026-07-22P/E 8.2-27%Fairly valued
2026-07-25P/E 8.0-28%Fairly valued
2026-07-27P/E 8.0-28%Fairly valued
2026-07-31P/E 8.2-27%Fairly valued
2026-08-03P/E 8.2-27%Fairly valued
2026-08-07P/E 8.6-24%Fairly valued
2026-08-10P/E 8.7-22%Fairly valued
2026-08-14P/E 8.8-22%Fairly valued
2026-08-17P/E 8.8-22%Fairly valued
2026-08-21P/E 9.1-19%Fairly valued ← now

Frequently asked questions

Is Pfizer stock overvalued?

At a blended P/E of 9.1 versus its historical normal P/E of 11.2, Pfizer trades about 19% below its typical valuation. tickerseer currently rates it fairly valued.

What is Pfizer's fair value and PEG?

Pfizer trades at a blended P/E of 9.1 against a historical normal P/E of 11.2, and a forward growth estimate of -8.9%.

Has tickerseer's rating of Pfizer changed?

tickerseer's rating has been fairly valued since 2026-06-03.

What is the analyst price target for Pfizer?

The mean Wall Street price target for Pfizer is $28.61 across 26 analysts, 1.9% above the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.

Industry: Pharmaceuticals. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.

See the full analysis →🔔 Track PFE free: valuation & earnings alerts

Get the free weekly earnings preview

One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.

It's free, and you can unsubscribe any time. Educational content, not investment advice.